Yujin Bio-Pharma Wuhan CNBG

Wuhan Yujin Bio-Pharma is a biotechnology company headquartered in Wuhan, China, specializing in the research and development of recombinant protein-based vaccines and biological products. The company gained international prominence through its partnership with the Wuhan Institute of Biological Products (WIBP), a division of the China National Biotec Group (CNBG/Sinopharm), to co-develop a recombinant protein COVID-19 vaccine (NVSI-06-07). This vaccine platform utilizes an insect cell expression system and has been evaluated in large-scale Phase 3 clinical trials across multiple countries. Wuhan Yujin's technological focus includes protein expression, purification, and the development of proprietary vaccine adjuvants. The company is a key participant in the Optics Valley biotech cluster, contributing to China's domestic vaccine innovation and global health initiatives. Beyond COVID-19, the company is advancing a pipeline of recombinant vaccines for other infectious diseases, such as rabies.